DelveInsight’s, “Uveitis – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Uveitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Uveitis Understanding
Uveitis: Overview
Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. These diseases can slightly reduce vision or lead to severe vision loss. The term “uveitis” is used because the diseases often affect a part of the eye called the uvea. Nevertheless, uveitis is not limited to the uvea. These diseases also affect the lens, retina, optic nerve, and vitreous, producing reduced vision or blindness. Uveitis may be caused by problems or diseases occurring in the eye or it can be part of an inflammatory disease affecting other parts of the body.
Symptoms
Uveitis can affect one or both eyes. Symptoms may develop rapidly and can include:
• Blurred vision
• Dark, floating spots in the vision (floaters)
• Eye pain
• Redness of the eye
• Sensitivity to light (photophobia)
Anyone suffering eye pain, severe light sensitivity, and any change in vision should immediately be examined by an ophthalmologist. The signs and symptoms of uveitis depend on the type of inflammation.
Diagnosis
Diagnosis of uveitis includes a thorough examination and the recording of the patient’s complete medical history. Laboratory tests may be done to rule out an infection or an autoimmune disorder. A central nervous system evaluation will often be performed on patients with a subgroup of intermediate uveitis, called pars planitis, to determine whether they have multiple sclerosis which is often associated with pars planitis. The eye exams used include:
• An Eye Chart or Visual Acuity Test
• A Funduscopic Exam
• Ocular Pressure
• A Slit Lamp Exam
Treatment
Uveitis treatments primarily try to eliminate inflammation, alleviate pain, prevent further tissue damage, and restore any loss of vision. Treatments depend on the type of uveitis a patient displays. Some, such as using corticosteroid eye drops and injections around the eye or inside the eye, may exclusively target the eye whereas other treatments, such immunosuppressive agents taken by mouth, may be used when the disease is occurring in both eyes, particularly in the back of both eyes. Long-term steroid use may produce side effects such as stomach ulcers, osteoporosis (bone thinning), diabetes, cataracts, glaucoma, cardiovascular disease, weight gain, fluid retention, and Cushing’s syndrome.
Other immunosuppressive agents that are commonly used include medications such as methotrexate, mycophenolate, azathioprine, and cyclosporine.
Uveitis Emerging Drugs Chapters
This segment of the Uveitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Uveitis Emerging Drugs
• Baricitinib: Eli Lilly and Company
Eli Lily is conducting an open-label, active-controlled, safety, and efficacy study of oral baricitinib in patients from 2 years to less than 18 years old with active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis. The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.
• EYS606: Eyevensys
Eyevensys' lead product EYS606 is a potential new treatment for patients with chronic non-infectious uveitis (NIU). EYS606 combines Eyevensys' proprietary Electrotransfection System with plasmids encoding for the production of a potent fusion protein which neutralizes the activity of TNFα, a cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in NIU. EYS606 is currently in a phase I/II clinical trial in the EU and has been granted an Orphan drug designation by the European Medicines Agency (EMA) for the treatment of NIU. The therapeutic potential of EYS606 in patients with active, chronic NIU will be further investigated in Part 2 of the ongoing EYS606-CT1 study in the EU and in a second phase 2 trial, the Electro Study (EYS606-CT2) that will be launched in the US in early 2020.
Further product details are provided in the report……..
Uveitis: Therapeutic Assessment
This segment of the report provides insights about the different Uveitis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Uveitis
There are approx. 10+ key companies which are developing the therapies for Uveitis. The companies which have their Uveitis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Gilead Sciences, Eyevensys, EyeGate Pharm etc.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Molecule Type

Products have been categorized under various Molecule types such as
• Small molecules
• Gene therapies
• Pregnadienetriols
• Glucocorticoids
• Fluorinated steroids

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uveitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uveitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uveitis drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Uveitis R&D. The therapies under development are focused on novel approaches to treat/improve Uveitis.
• September 2020: Reimbursement approved for Iluvien for noninfectious posterior uveitis in Scotland.
o The Scottish Medicines Consortium has accepted Iluvien for prevention of relapse in recurrent noninfectious posterior segment uveitis, Alimera announced in a press release.
Uveitis Report Insights
• Uveitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Uveitis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Uveitis drugs?
• How many Uveitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uveitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Uveitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Uveitis and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Eli Lilly and Company
• AbbVie
• Gilead Sciences
• Eye Pharma
• Panoptes Pharma GmbH
• Santen Inc.
• Tarsius Pharma
• Eyevensys
Key Products
• Baricitinib
• Filgotinib
• PP-001
• EYS606
• TRS01 eye drops
• pEYS606
• Apremilast